Full Breakdown
Trump Administration Accelerates Psychedelic Research and Marijuana Rescheduling
4/25/2026, 9:25:48 PM
Executive Orders and Funding
In early 2026 President Donald Trump signed an executive order earmarking $50 million for psychedelic research and ordering the Food and Drug Administration to fast-track reviews. Acting Attorney General Todd Blanche reclassified medical marijuana to a lower schedule and asked the Drug Enforcement Administration to consider a downgrade for recreational use.
Context
The move departs from the Nixon-era “Just Say No” doctrine, reflecting a “Make America Healthy Again” agenda fueled by rising public support for cannabis, psychedelic-therapy data, veteran advocacy, and allies such as podcaster Joe Rogan and entrepreneur Elon Musk.
Key Players
Key sponsors are President Trump, Acting AG Todd Blanche, HHS Secretary Robert F. Kennedy Jr., Rep. Morgan Luttrell (R-TX) and Rep. Jack Bergman (R-MI) of the Congressional Psychedelics Advancing Therapies Caucus, plus industry advocates Bryan Hubbard of Americans for Ibogaine and Adam Rosenberg of the National Cannabis Industry Association.
Official Statements
The White House described the actions as expanding treatment options for veterans and others with substance-use disorders. The Justice Department said the marijuana reclassification fulfills President Trump’s pledge to broaden medical access. The FDA has already rejected an ecstasy-based PTSD therapy, showing limits to the fast-track approach.
Opposition
Eagle Forum chair Anne Schlafly Cori warned Trump “doesn’t realize the dangers he is unleashing.” Twenty-two Senate Republicans urged a halt to marijuana rescheduling, citing health and economic risks. Sen. Tom Cotton (R-AR) warned cannabis is linked to psychosis, antisocial behavior and fatal crashes. Anti-legalization advocate Kevin Sabet called the administration “the most pro-drug administration in our history.”
Verbatim Quotes
- “Can I have some, please?” — Donald Trump, President of the United States
- “is delivering on President Trump’s promise to expand Americans’ access to medical treatment options.” — Todd Blanche, Acting Attorney General
- “Regardless of what one may think of the president … he seems to be someone who is open to innovation and is not imprisoned by dogmatic viewpoints,” — Bryan Hubbard, CEO, Americans for Ibogaine
- “With this imminent move, we are now confronted with the most pro-drug administration in our history,” — Kevin Sabet, CEO, Smart Approaches to Marijuana
Conflicting Reports
The order’s fast-track directive does not change psychedelics’ Schedule I status, and the FDA’s rejection of an ecstasy-based PTSD treatment shows approval is not assured. While the DOJ lowered medical marijuana’s schedule, recreational cannabis remains Schedule I pending DEA action, leaving reforms incomplete.
Outlook
The FDA is slated to start accelerated reviews of psychedelic candidates, and the DEA faces pressure to consider further marijuana rescheduling. Congressional advocates continue to push legislation, but intra-party opposition may shape future amendments, determining whether the “soft-drug” reforms become lasting policy.
